-+ 0.00%
-+ 0.00%
-+ 0.00%

Junshi Biotech said at the 2026 semi-annual results briefing held on September 14 that phase III clinical research of the company's new drug JS203 is expected to begin within 2026; JS207 is already in phase II clinical research. Joint exploration with different drugs such as chemotherapy, monoclonal antibodies, and ADC is being carried out in multiple tumors, and phase III clinical research is scheduled to begin within 2026.

Zhitongcaijing·09/14/2026 05:25:06
Listen to the news
Junshi Biotech said at the 2026 semi-annual results briefing held on September 14 that phase III clinical research of the company's new drug JS203 is expected to begin within 2026; JS207 is already in phase II clinical research. Joint exploration with different drugs such as chemotherapy, monoclonal antibodies, and ADC is being carried out in multiple tumors, and phase III clinical research is scheduled to begin within 2026.